

Jason Valent

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/289711/publications.pdf>

Version: 2024-02-01

33
papers

499
citations

840776

11
h-index

713466

21
g-index

33
all docs

33
docs citations

33
times ranked

841
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2941-2948.	2.8	84
2	Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. <i>Blood Cancer Journal</i> , 2021, 11, 10.	6.2	53
3	Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center's experience. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 197-202.	3.0	51
4	Daratumumab proves safe and highly effective in <sc>AL</sc> amyloidosis. <i>British Journal of Haematology</i> , 2019, 185, 342-344.	2.5	46
5	Treatment of relapsed multiple myeloma: Evidence-based recommendations. <i>Blood Reviews</i> , 2020, 39, 100616.	5.7	43
6	Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma. <i>British Journal of Haematology</i> , 2020, 189, 1136-1140.	2.5	25
7	Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. <i>British Journal of Haematology</i> , 2021, 193, 1213-1219.	2.5	25
8	Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. <i>PLoS ONE</i> , 2017, 12, e0172996.	2.5	20
9	Emerging Advances in the Management of Cardiac Amyloidosis. <i>Current Cardiology Reports</i> , 2015, 17, 100.	2.9	19
10	Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Hematological Oncology</i> , 2020, 38, 353-362.	1.7	14
11	Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 397-405.	0.4	13
12	Progression with clinical features is associated with worse subsequent survival in multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 439-445.	4.1	12
13	Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. <i>Blood</i> , 2020, 136, 48-50.	1.4	11
14	Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis. <i>Blood</i> , 2020, 136, 21-21.	1.4	9
15	DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Seminars in Hematology</i> , 2021, 58, 45-55.	3.4	8
16	Monoclonal gammopathy of undetermined significance: A primary care guide. <i>Cleveland Clinic Journal of Medicine</i> , 2019, 86, 39-46.	1.3	8
17	Solitary extramedullary plasmacytoma of the penis. <i>Urology Annals</i> , 2014, 6, 242.	0.6	7
18	Diagnostic challenges in POEMS syndrome presenting with polyneuropathy: A case series. <i>Journal of the Neurological Sciences</i> , 2017, 378, 170-174.	0.6	7

#	ARTICLE	IF	CITATIONS
19	Cael-101 Is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (Cybord): A Phase 2 Dose-Finding Study (NCT04304144). <i>Blood</i> , 2020, 136, 26-27.	1.4	7
20	Palliative Care in Patients With Multiple Myeloma. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 1113-1118.	1.2	6
21	Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy. <i>Blood Cancer Journal</i> , 2021, 11, 121.	6.2	6
22	Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia). <i>Advances in Hematology</i> , 2022, 2022, 1-9.	1.0	6
23	A 70-Year-Old Man With Large Cervical and Mediastinal Lymphadenopathies. <i>Chest</i> , 2015, 148, e8-e13.	0.8	4
24	Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma. <i>Blood</i> , 2018, 132, 1899-1899.	1.4	3
25	Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2016, 6, 21.	2.7	2
26	Monoclonal IgM gammopathy in adult acquired pure red cell aplasia: culprit or innocent bystander?. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 91, 102595.	1.4	2
27	Once Weekly Subcutaneous Bortezomib, Cyclophosphamide, and Dexamethasone As Induction Therapy for All AL Amyloidosis. <i>Blood</i> , 2016, 128, 5813-5813.	1.4	2
28	Progress in diagnosing and managing cardiac amyloidosis. <i>Cleveland Clinic Journal of Medicine</i> , 2019, 86, 29-37.	1.3	2
29	Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the <i>PRISM</i> score. <i>Blood</i> , 2020, 136, 29-30.	1.4	2
30	Supra-normal left ventricular ejection fraction in cardiac amyloidosis. <i>Clinical Research in Cardiology</i> , 2023, 112, 441-443.	3.3	2
31	Response-Adapted Therapy for Newly Diagnosed Myeloma. <i>Blood</i> , 2016, 128, 3606-3606.	1.4	0
32	A Novel Therapeutic Strategy for Preferential Elimination of Multiple Myeloma Cells By Targeting Protein Disulfide Isomerase. <i>Blood</i> , 2020, 136, 32-33.	1.4	0
33	Outcomes in AL Amyloidosis: A Single Institution Experience. <i>Blood</i> , 2020, 136, 32-32.	1.4	0